For example, while PD-1/PD-L1 blockade monotherapy has achieved a satisfactory response in patients with different cancers, a meta-analysis demonstrated that approximately four-fifths of patients do not respond to PD-1/PD-L1 monotherapy in clinical trials [11]. Here, CD274 is linked to cancer.